



Universiteit  
Leiden  
The Netherlands

## **Attendance characteristics of the breast and colorectal cancer screening programmes in a highly urbanised region of the Netherlands: a retrospective observational study**

Bongaerts, T.H.G; Buchner, F.L.; Munck, L. de; Elferink, M.A.G.; Guicherit, O.R.; Numans, M.E.

### **Citation**

Bongaerts, T. H. G., Buchner, F. L., Munck, L. de, Elferink, M. A. G., Guicherit, O. R., & Numans, M. E. (2023). Attendance characteristics of the breast and colorectal cancer screening programmes in a highly urbanised region of the Netherlands: a retrospective observational study. *Bmj Open*, 13(6). doi:10.1136/bmjopen-2022-071354

Version: Publisher's Version

License: [Creative Commons CC BY-NC 4.0 license](https://creativecommons.org/licenses/by-nc/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3638699>

**Note:** To cite this publication please use the final published version (if applicable).

# BMJ Open Attendance characteristics of the breast and colorectal cancer screening programmes in a highly urbanised region of the Netherlands: a retrospective observational study

Thomas H G Bongaerts <sup>1,2</sup>, Frederike L Büchner <sup>1,2</sup>, Linda de Munck,<sup>3</sup> Marloes A G Elferink,<sup>3</sup> Onno R Guicherit <sup>4</sup>, Mattijs E Numans <sup>1,2</sup>

**To cite:** Bongaerts THG, Büchner FL, de Munck L, *et al.* Attendance characteristics of the breast and colorectal cancer screening programmes in a highly urbanised region of the Netherlands: a retrospective observational study. *BMJ Open* 2023;**13**:e071354. doi:10.1136/bmjopen-2022-071354

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2022-071354>).

Received 28 December 2022  
Accepted 13 June 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

## Correspondence to

Thomas H G Bongaerts;  
t.h.g.bongaerts@lumc.nl

## ABSTRACT

**Objectives** Throughout Europe, many countries offer population-based cancer screening programmes (CSPs). In the Netherlands, two implemented CSPs are targeting people of 50 years and older, aiming at breast cancer (BC) and colorectal cancer (CRC). In order for a CSP to be (cost-)effective, high participation rates and outreach to the populations at risk are essential. People living in highly urbanised areas and big cities are known to participate less in CSPs. The aim of this study was to gain further insight into the participation patterns of a screening-eligible population of 50 years and over, living in a highly urbanised region, over a longer time period.

**Design** A retrospective observational study.

**Setting** Participation data of the regional screening organisation, linked to the cancer incidence data derived from the Netherlands Cancer Registry, concerning the city of The Hague, between 2005 and 2019. Attendance groups were defined as attenders (attending >50% of the invitations) and non-attenders (attending ≤50% of the invitations), and were mutually compared.

**Results** The databases contained 106 377 unique individuals on the BC screening programme (SP) and 73 669 on the CRC-SP. Non-attendance at both CSPs was associated with living in a lower socioeconomic status (SES) neighbourhood and as a counter effect, also associated with a more unfavourable, relatively late-stage, tumour diagnosis. When combining the results of the two CSPs, our results imply high screening adherence over time. Women who did not participate in both CSPs were older, and more often lived in neighbourhoods with a lower SES score.

**Conclusions** Since low screening uptake is one of the factors that contribute to increasing inequalities in cancer survival, future outreach strategies should be focused on engaging specific non-attending subgroups.

## INTRODUCTION

Many European countries offer population-based cancer screening programmes (CSPs) to its inhabitants.<sup>1</sup> The most common screening programmes (SPs) in Europe focus at the early

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ For this study, regional screening invitation and attendance data were combined with cancer incidence data from the Netherlands Cancer Registry.
- ⇒ By comparing the breast and colorectal cancer screening programmes, it allowed comparing a long-term programme with a relatively new programme.
- ⇒ The city of The Hague can be seen as true 'living lab' to test for differences in screening attendance between different subgroups, due to strong differences between the different neighbourhoods, all well represented by socioeconomic status scores.
- ⇒ Since the colorectal cancer is a relative new screening programme, data were only available on the implementation phase of the programme.

detection of cervical, breast and colorectal cancer (CRC).<sup>1</sup> CSPs aim to detect cancers in an early or precursor stage, and thereby improving chances of survival due to early intervention. Early intervention is thought to lead to a better prognosis, and to less extensive treatment options.<sup>2-4</sup> Also, in the Netherlands, there are currently three CSPs implemented. The SPs concerning breast cancer (BC) and CRC are most comparable, both target the same age groups (starting at 50 and 55 years of age, respectively), and biennially invite potential participants.<sup>5</sup> While the BC-SP was phased in as early as 1990 and reached national coverage in 1996,<sup>6</sup> the CRC-SP was only phased in from 2014, and has only been fully operational since 2019.<sup>7</sup>

For an SP to be (cost-)effective, it is important that as many of the potential participants that are targeted, indeed participate.<sup>8,9</sup> The WHO suggests that at least 70% of a target population should actually be screened, for the SP in order to be beneficial to population health.<sup>10-12</sup> Throughout

Europe attendance at CSPs varies substantially, yet the Netherlands is known for its high attendance rates.<sup>1</sup> Latest Dutch attendance rates—from before the COVID-19 pandemic—were 76% and 72%, for the BC-SP and CRC-SP, respectively.<sup>13 14</sup> Although these numbers might seem reassuring on a national level, the attendance rates were already declining gradually over the past years, and regional differences in screening attendance increased.<sup>15</sup> Current screening uptake is lowest in the highly urbanised areas and big cities of the Netherlands, and in neighbourhoods with low socioeconomic status (SES).<sup>16</sup>

The city of The Hague is the third largest city of the country and represents a densely populated area, with a rich mixture of different cultures and ethnicities, and with major differences in health outcomes between various neighbourhoods. In 2019, The Hague's average attendance rates were 64% and 57%, for the BC-SP and CR-CSP, respectively.<sup>17</sup> Hence, both are below the minimal intended rate of 70%.

To be able to promote participation in CSPs, it is important that the programmes are designed and operate as well as possible, and are in accordance with the targeted populations. Further insight into the characteristics of attenders and non-attenders, especially in highly urbanised regions, is thus needed. The aim of this study was to gain insight into the background of differing attendance patterns of a screening-eligible population aged 50 years and over, living in a highly urbanised and diverse region, over a relatively longer period of time.

## METHODS

A retrospective observational study was performed among all screening-eligible people concerning the BC-SP and the CRC-SP living in The Hague, the Netherlands, between 2005 and 2019.

### Screening programmes in the Netherlands

The Netherlands hosts CSPs aimed at cervical, breast and CRC. Screening participation is on a voluntary basis, and the screening tests are offered free of charge by the Dutch government.<sup>5</sup>

The BC-SP biennially invites women between 50 and 75 years of age, and uses a bilateral mammography as a screening tool. To participate in this CSP, women must schedule their own appointments. After an abnormal screening result the participant will be referred to the hospital by the general practitioner (GP).<sup>6</sup>

The CRC-SP biennially invites both women and men aged between 55 and 75 years, and uses a faecal immunochemical test (FIT) as screening tool. The FIT can be performed at home. After a positive FIT, participants will be scheduled for a coloscopy in a contracted colonoscopy centre by the screening organisation.<sup>7</sup>

### Data management

In the Netherlands, The National Institute for Public Health and the Environment (Rijksinstituut voor Volksgezondheid en Milieu, RIVM) and the national screening

organisation are in charge of organising and coordinating the CSPs. Detailed data on national participation rates are publicly available through the RIVM website.<sup>5</sup> Regional screening invitation and attendance data were retrieved via the national screening organisation, region South-West (Bevolkingsonderzoek Zuid-West, BVO-ZW). Cancer incidence data were retrieved from the Netherlands Cancer Registry via the Netherlands Comprehensive Cancer Organisation (Integraal Kankercentrum Nederland, IKNL).<sup>18</sup> Both datasets were linked on an individual level by IKNL after approval from the privacy officers of both organisations. As researchers, we only had access to aggregated data. At time of the data extraction (2020), most recent complete datasets were extracted relating to the screening data of BVO-ZW. For the BC-SP, extracted data were from 2005 to 2019. For the CRC-SP, extracted data was from 2014 to 2019. Since the CRC-SP was only fully integrated and functioning from 2019, included data were of the implementation phase of the CRC-SP.

The BVO-ZW-database contained the variables: gender; year of birth; four-digit zip code, tests results: mammography and colonoscopy. The NCR-database contained the variables: gender, year of birth, date of diagnosis of the tumour, tumour type (BC/CRC) and tumour stage. Within the combined dataset several new variables were determined: 'number of times invited', 'number of times participated' and 'percentage participated after being invited'.

For every four-digit zip code, a neighbourhood SES score was set by the Netherlands Institute for Social Research (Sociaal en Cultureel Planbureau) on a continuous scale in 2017.<sup>19</sup> This score incorporates data on house value and income. We categorised this score into quartiles (1–4: the higher the number, the higher the SES), including all neighbourhoods in the Netherlands. Thereafter, the four-digit zip code for neighbourhoods of The Hague were assigned with a neighbourhood SES score.

### Data analysis

The subdivision of attendance groups for both CSPs was determined over the set time period: how many people were invited, how many people did participate, and how many people were registered with a cancer diagnosis. We distinguished invitees who always (100%), sometimes (>0% and <100%) and never (0%) participated after receiving an invitation.

For further analysis, we divided our data into 'attenders' and 'non-attenders'. Attenders were defined as: invitees who participated in the CSPs in more than 50%, after being invited. Non-attenders were defined as: invitees who participated in 50% or less, after being invited. This categorisation was chosen based on the distribution of attendance and rules of thumb. The proportion of attenders and non-attenders was presented descriptively, using counts and percentages. To test independent continuous variables, Mann-Whitney U and Kruskal-Wallis tests were conducted. For categorical independent variables, univariate regression analyses were performed with an  $\alpha$  0.05

and  $\beta$  0.8. This resulted in ORs per attendance group, with corresponding 95% CIs. Likelihood ratio tests were performed to test for the influence of each independent variable in the regression models. Our data were stored and analysed by making use of IBM SPSS (V.25).

### Patient and public involvement

The development of the research question, study design and outcome measures was carried out by a team of experienced primary care and secondary care physicians and researchers, who also concerned patients' and public's interests. Patients were not directly involved in these processes. The results of this research work are going to be published open access and disseminated to whom is interested, among others primary care doctors and the Municipal Health Services.

### Results

The databases contained 106 377 unique individuals on the BC-SP, and 73 669 on the CRC-SP. Analysis showed an overlap of 38 071 individuals, thus around a third, receiving invitations for both CSPs.

#### Breast cancer screening programme

Most women received seven invitations (27.0%), with a maximum of nine invitations (0.1%). Within the time period of 14 years,  $n=48\,126$  women (45.2%) received their first BC-SP invitation. In total,  $n=79\,594$  women (74.8%) participated at least once. Among the invitees,  $n=3820$  (3.6%) women were diagnosed with BC, regardless of whether this tumour was screen detected.

The largest group of BC-SP invitees always participated in the CSP after receiving an invitation ( $n=47\,087$ ; 44.3%). About a quarter of the invited women never participated ( $n=26\,783$ ; 25.2%). Among the 'always-attenders', 1.6%

( $n=755$ ) of the women were diagnosed with BC, compared with 6.8% ( $n=2198$ ) and 3.2% ( $n=867$ ) of the 'sometimes' and 'never-attenders', respectively (online supplemental figure 1).

A total of 61.9% ( $n=65\,853$ ) of the invitees were identified as 'attenders', hence 38.1% ( $n=40\,524$ ) as 'non-attenders'. Non-attenders were found to be 2 years younger (Mann-Whitney U:  $p<0.01$ ). The amount of BCs were evenly divided between the two attendance groups (50.6% vs 49.4%). Women in the non-attenders group with BC, were 2 years younger (Mann-Whitney U:  $p<0.01$ ), and diagnosed with BC 5 years earlier in live (Mann-Whitney U:  $p<0.01$ ), compared with women with BC in the attenders group (table 1).

The neighbourhood SES score differed statistically significant between attenders and non-attenders (likelihood ratio test:  $p<0.01$ ). Women living in a neighbourhood with the highest SES scores were more likely to participate (ascending ORs from 1.29 to 1.50; for SES-2 to SES-4, compared with SES-1). The neighbourhood SES scores were not statistical different between the different attendance groups with BC (likelihood ratio test:  $p=0.08$ ). Despite, people living in an SES-4 neighbourhood were more likely to participate (OR 1.22), compared with people living an SES-1 neighbourhood. Attendance was associated with a lower BC stage (declining ORs from 0.95 to 0.15). In addition, when the interaction effect for both independent variables was determined, non-attenders were more likely to live in neighbourhoods with lower SES score, and had the more unfavourable cancer stages as an outcome (likelihood ratio test:  $p<0.01$ ) (table 2).

**Table 1** Characteristics invitees and cancer cases, concerning the breast cancer screening programme

Attendance group*	Total invitees ( $n=106\,377$ )		Invitees with BC ( $n=3820$ )					
	Attenders	Non-attenders	Attenders		Non-attenders			
Proportion % (n)	61.9 (65 853)	38.1 (40 524)	50.6 (1932)		49.4 (1888)			
Year of birth Median (25%–75%)	1953 (1945–1960)	1955 (1945–1962)	1948 (1942–1954)		1950 (1944–1957)			
Age at diagnosis Median (25%–75%)	–	–	65 (59–71)		60 (54–67)			
Neighbourhood SES score	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>		
1	17 656	30.5	12 813	38.4	520	27.9	560	31.0
2	12 127	21.0	6 829	20.5	391	20.9	398	22.0
3	4 488	7.8	2 301	6.9	145	7.8	132	7.3
4	23 539	40.7	11 384	34.2	811	43.4	718	39.7
Unknown	8 043		7 197		65		80	

\*Attenders: people who participated in >50%, after being invited. Non-attenders: people who participated in ≤50%, after being invited. BC, breast cancer; SES, socioeconomic status.



**Table 2** Results univariate regression analyses on attendance, concerning invitees and breast cancer cases

	OR (95% CI)	P value	n
SES (invitees)			
SES 1	Reference	<0.01*	30 469
SES 2	1.29 (1.24 to 1.34)	<0.01*	18 956
SES 3	1.42 (1.34 to 1.50)	<0.01*	6 789
SES 4	1.50 (1.45 to 1.55)	<0.01*	34 923
SES (invitees with BC)			
SES 1	Reference	0.08	1 080
SES 2	1.06 (0.89 to 1.27)	0.55	789
SES 3	1.18 (0.91 to 1.54)	0.21	277
SES 4	1.22 (1.04 to 1.42)	0.01*	1 529
Stage			
CIS	Reference	<0.01*	517
Stage 1	0.95 (0.78 to 1.16)	0.61	1 469
Stage 2	0.49 (0.40 to 0.61)	<0.01*	1 116
Stage 3	0.32 (0.24 to 0.42)	<0.01*	316
Stage 4	0.15 (0.10 to 0.24)	<0.01*	156
SES×stage			
SES 4×CIS	Reference	<0.01*	217
SES 4×stage 1	0.78 (0.57 to 1.09)	0.15	620
SES 4×stage 2	0.46 (0.33 to 0.64)	<0.01*	465
SES 4×stage 3	0.35 (0.22 to 0.56)	<0.01*	125
SES 4×stage 4	0.17 (0.09 to 0.32)	<0.01*	62
SES 3×CIS	0.59 (0.30 to 1.18)	0.13	38
SES 3×stage 1	0.68 (0.43 to 1.08)	0.10	119
SES 3×stage 2	0.54 (0.33 to 0.88)	0.01*	93
SES 3×stage 3	0.20 (0.07 to 0.59)	0.01*	18
SES 3×stage 4	0.00 (0.00 to 0.00)	1.00	1
SES 2×CIS	0.82 (0.51 to 1.32)	0.41	107
SES 2×stage 1	0.84 (0.59 to 1.21)	0.35	319
SES 2×stage 2	0.32 (0.22 to 0.47)	<0.01*	229
SES 2×stage 3	0.26 (0.15 to 0.44)	<0.01*	82
SES 2×stage 4	0.13 (0.05 to 0.34)	<0.01*	30
SES 1×CIS	0.71 (0.47 to 1.09)	0.12	155
SES 1×stage 1	0.78 (0.56 to 1.10)	0.15	411
SES 1×stage 2	0.38 (0.26 to 0.54)	<0.01*	329
SES 1×stage 3	0.18 (0.10 to 0.31)	<0.01*	91
SES 1×stage 4	0.09 (0.04 to 0.19)	<0.01*	63

\*Statistically significant associated with attendance at the cancer screening programmes.  
BC, breast cancer; CIS, carcinoma in situ; SES, socioeconomic status.

### Colorectal cancer screening programme

Most invitees received one invitation (48.2%), with a maximum of three invitations (12.8%). Since all acquired data were from the implementation period of the SP, all

invitees received their first invitation during the set time period. In total, n=70 638 (95.9%) people participated at least once. Among the invitees, n=515 (0.7%) were diagnosed with CRC, regardless of whether this tumour was screen detected. The amount of male participants with CRC was 1.2 times higher, compared with female participants (55% (n=284) vs 45% (n=231)).

The largest group of CRC-SP invitees always participated in the CSP after receiving an invitation (n=583 793; 79.8%). Only a very small part of the invitees never participated (n=3034; 4.1%). Among the 'always attenders', 0.7% (n=396) of the participants were diagnosed with CRC, compared with 0.8% (n=93) and 0.9% (n=26) of the 'sometimes' and 'never-attenders', respectively (online supplemental figure 2).

A total of 83% (n=61 132) of the invitees were identified as 'attenders', hence 17% (n=12 537) as 'non-attenders'. In the attenders group, 46.5% of the people were male, compared with 47.4% in the non-attenders group (likelihood ratio: p=0.08). Median age of the non-attenders was found to be 2 years older (Mann-Whitney U: p<0.01). Most CRCs were found in the attenders group (79.2% vs 20.8%). Median age of the invitees in the non-attenders group with CRC was 1 year lower (Mann-Whitney U, p=0.27), but they were diagnosed with CRC around the same median age (Mann-Whitney U, p=0.67), compared with invitees with CRC in the attenders group (table 3).

The neighbourhood SES score differed statistically significant between attenders and non-attenders (likelihood ratio test: p<0.01). Invitees living in a neighbourhood with the highest SES scores were the more likely to participate (ascending ORs from 1.43 to 1.66; for SES-2 to SES-4, compared with SES 1). The neighbourhood SES scores also differed statistically between the different attendance groups with CRC (likelihood ratio test: p=0.05). People living in an SES-2 neighbourhood were more likely to participate (OR 1.64), compared with people living in an SES-1 neighbourhood. Attendance was not statistical different between the several CRC stages. Despite, a stage 4 CRC had an OR of 0.56 on attendance, compared with a stage 1. In addition, when the interaction effect for both independent variables was determined, no statistical differences could be established (likelihood ratio test: p=0.24). However, when taken the ORs (SES 1×stages 2–4) into account non-attenders, there seems to be a tendency that non-attenders were more likely to live in neighbourhoods with lower SES scores, and had the more unfavourable cancer stages (table 4).

### Comparison of the two screening programmes

In total, n=38 071 women were invited for both CSPs. Most of these women attended both programmes, n=26 560 (69.8%). Only a small amount of women did not participate in any programme, n=1 679 (4.4%). Between the four different subgroups, both 'year of birth' (Kruskal-Wallis: p<0.01) and 'neighbourhood SES score' were statistically different (likelihood ratio: p<0.01). Women who did not attend the BC-SP, but did attend the CRC-SP

**Table 3** Characteristics invitees and colorectal cancer cases, concerning the colorectal cancer screening programme

	Total invitees (n=73 669)		Invitees with CRC (n=515)					
	Attendees	Non-attendees	Attendees	Non-attendees				
Attendance group*	Attendees	Non-attendees	Attendees	Non-attendees				
Proportion % (n)	83.0 (61 132)	17.0 (12 537)	79.2 (408)	20.8 (107)				
Sex % (n)	M: 46.5 (28 450) F: 53.5 (32 681)	M: 47.7 (5974) F: 52.3 (6563)	M: 53.9 (220) F: 46.1 (188)	M: 59.8 (64) F: 40.2 (43)				
Year of birth Median (25%–75%)	1953 (1947–1958)	1951 (1947–1954)	1948 (1945–1953)	1949 (1946–1952)				
Age at diagnosis Median (25%–75%)	–	–	67 (55–77)	67 (64–69)				
Neighbourhood SES score	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>		
1	16 908	27.8	4 693	37.6	110	27.0	41	38.3
2	12 664	20.8	2 453	19.7	103	25.2	11	10.3
3	4 697	7.7	869	7.0	38	9.3	7	6.5
4	26 546	43.7	4 451	35.7	157	38.5	48	44.9
Unknown	317		71		0		0	

\*Attendees: people who participated in >50%, after being invited. Non-attendees: people who participated in ≤50%, after being invited. CRC, colorectal cancer; F, female; M, male; SES, socioeconomic status.

were the youngest, with a median year of birth of 1954. Non-attendees tended to live more in the neighbourhoods with lower SES scores. Especially non-attendance at the CRC-SP seemed to be associated with lower an SES score (BC+, CRC–; SES score 1=37.3%, and BC–, CRC–; SES score 1=40.7%, compared with BC+, CRC+; SES score 1=27.5%) (online supplemental table 1).

## DISCUSSION

This retrospective observational study, among people eligible for attending the BC-SP and CRC-SP, conducted in a highly urbanised region between 2005 and 2019, delivered multiple insights concerning screening attendance, screening adherence and cancer risks within subgroups. Non-attendance for both CSPs was found in lower SES neighbourhoods, which was already known, but it was also associated with a more unfavourable (late-stage) tumour diagnosis, which is new. When combining the results of the two CSPs, our results imply high screening adherence over time. Women who did not participate in both CSPs were older, and more often lived in neighbourhoods with a lower SES score.

Several studies conducted in the Netherlands did focus on SES as a determinant for screening attendance and/or adherence, and did report the same conclusion: living in a lower SES area/region/neighbourhood is associated with lower screening uptake.<sup>20–22</sup> Our study thus confirms this ‘SES effect’ and shows to remain valid, even within a highly urbanised region. Additionally, our study adds that non-attendees living in a lower SES neighbourhood, are more often diagnosed with a more unfavourable form of BC, and the same tendency seems to exist for

CRCs. In this study, we did not look into mechanisms on why people living in lower SES neighbourhoods developed these more unfavourable forms of cancer, but in literature factors related to health illiteracy are often mentioned.<sup>23</sup> Just recently, Kregting *et al* compared the screening attendance of women at the screening ages of 55/65 years, and concluded that women living in areas with higher population density and lower SES score were less likely to participated in more CSPs.<sup>24</sup> Three studies conducted in the UK compared barriers for the CSPs and concluded that women who lived in a more deprived region, participated less in the CSPs.<sup>25–27</sup> Age as a variable, was earlier described in two studies. One did not find any influence,<sup>25</sup> the other reported a lower age to be associated with lesser screening attendance.<sup>26</sup> Within our study, we saw a mixed influence of age, depending on the CSP. With respect to screening adherence, we found rather high overall screening attendance rates for both CSPs. The yearly monitoring reports of RIVM show the same high screening adherence on a national level.<sup>13 14</sup> In terms of cancer risk, we found that men were more likely to be diagnosed with CRC than women, which is consistent with national trends.<sup>14</sup> Hence, there should be a targeted endeavour to specifically engage male participants in the CRC-SP.

By conducting this study, we were able to compare a long-lasting programme with a relatively new programme. We focused on the city of The Hague since this highly urbanised, multiethnic and diverse city from our perspective can relatively easily act as a true ‘living lab’ to test for differences in screening attendance between different subgroups, due to strong differences between



**Table 4** Results univariate regression analyses on attendance, concerning invitees and colorectal cancer cases.

	OR (95% CI)	P value	n
SES (invitees)			
SES 1	Reference	<0.01*	21601
SES 2	1.43 (1.36 to 1.51)	<0.01*	15117
SES 3	1.50 (1.39 to 1.62)	<0.01*	5566
SES 4	1.66 (1.58 to 1.73)	<0.01*	30997
SES (invitees with CRC)			
SES 1	Reference	0.05*	151
SES 2	1.64 (1.18 to 2.26)	0.01*	114
SES 3	1.67 (1.05 to 2.64)	0.12	45
SES 4	1.56 (1.19 to 2.05)	0.42	205
Stage			
Stage 1	Reference	0.38	198
Stage 2	0.76 (0.43 to 1.36)	0.36	109
Stage 3	0.80 (0.47 to 1.38)	0.43	147
Stage 4	0.56 (0.29 to 1.08)	0.09*	61
SES×stage			
SES 4×stage 1	Reference	0.24	78
SES 4×stage 2	1.25 (0.49 to 3.17)	0.64	39
SES 4×stage 3	1.12 (0.50 to 2.49)	0.79	58
SES 4×stage 4	0.89 (0.34 to 2.31)	0.80	30
SES 3×stage 1	2.15 (0.57 to 8.03)	0.26	23
SES 3×stage 2	>10.00 (0.00->10.00)	1.00	9
SES 3×stage 3	0.97 (0.18 to 5.19)	0.97	8
SES 3×stage 4	0.48 (0.08 to 3.11)	0.44	5
SES 2×stage 1	3.46 (1.10 to 10.91)	0.03*	47
SES 2×stage 2	1.85 (0.57 to 6.03)	0.31	27
SES 2×stage 3	4.83 (1.06 to 22.13)	0.04*	32
SES 2×stage 4	2.25 (0.26 to 19.51)	0.46	8
SES 1×stage 1	1.45 (0.60 to 3.56)	0.40	50
SES 1×stage 2	0.59 (0.25 to 1.13)	0.24	34
SES 1×stage 3	0.81 (0.36 to 1.81)	0.60	49
SES 1×stage 4	0.64 (0.21 to 2.00)	0.44	18
*Statistically significant associated with attendance at the cancer screening programmes. CRC, colorectal cancer; SES, socioeconomic status.			

the different neighbourhoods, all well represented by the SES scores.<sup>28</sup> This also allows our study findings to be directly translated and straight forward applied into daily practice. While the segregation between neighbourhoods in The Hague is probably the most evident, we expect our findings to be also applicable for other large cities, as for example, Amsterdam and Rotterdam, given their generally comparable demographic characteristics.<sup>29–31</sup>

Our study has some limitations that need to be reflected on. Since the CRC-SP is a relative new CPS, we only had access to data of the implementation phase of the CSP,

over a period of 4 years. This resulted in relatively little data on the CRC-SP, compared with the data on the BC-SP, and in particular resulted in small CRC numbers. Further research, in a later stage of the programme, might therefore be worthwhile once additional data become accessible regarding the CRC-SP. This would enable the execution of regression analyses with potential adjustments for variables including age, gender and screening round. Then it could also be considered whether our used cut-off point for ‘attenders’ and ‘never-attenders’ is still the most appropriate. Although we do not expect other conclusion for our analysis with for example a cut-off value of 60%, this might be different when more data is available. For this purpose, a sensitivity analysis could be conducted. Furthermore, one might question the relevance of comparing the data of a CSP in the implementation phase, with a ‘steady state’ CSP. We, however, felt it was just relevant to compare the two CSPs already at this early stage, as any shortcomings could then be addressed earlier. The chosen screening tests will, of course, always have an effect on the attendance rates. Another limitation has to do with the degree of crudeness of our variables. In the initial study design, we planned to look into several specific characteristics of potential participants and their association with screening attendance. However, despite the large number of invited people by the CPSs, adding more patient-specific characteristics would potentially lead to identification of individual participants, which would cause serious privacy issues. To avoid this risk, we decided to only look at relatively undetailed patient characteristics, such as: year of birth, age of diagnosis, sex and neighbourhood SES scores.

When thinking of clinical relevance and usability of the study findings, our main conclusion is that more, and more specifically targeted, effort should be implemented to engage people living in neighbourhoods with a lower SES score into these SPs. Current low attendance in these areas may lead to a further increasing inequality in cancer survival, in a subpopulation already confronted with several other health risks and problems. Our study underlines a longstanding hypothesis: people who are possibly the most at risk for the development of an advanced form of cancer, are the less likely to be screened.<sup>32</sup>

Future development, therefore, should focus on more specific outreach strategies to engage people living in neighbourhoods with a lower SES score that are at specific risk of non-attendance, as partly earlier suggested by Woudstra *et al.*<sup>33</sup> We suggest to encourage healthcare professionals, policymakers and politicians to look into such kind of ‘novel solutions’. We also suggest that GPs, or primary healthcare professionals in general, take on a more prominent role in promoting and educating people on the CSPs. Previous studies showed that GP involvement has a positive impact on (cervical) screening uptake, in particular for the classic ‘hard to reach’ subgroups.<sup>34 35</sup> Especially in deprived areas, people generally trust and have a good long-term relationship with their GP, and primary healthcare centres in these areas are the only



available link to enter healthcare and to gain information on health issues.<sup>36</sup> A remaining question would be, how exactly the role of GP practice centres should be improved while avoiding the risk to further increasing workload. Perhaps just being enlisted with a primary healthcare centre, and being invited to participate through that centre, could already make a difference.

## CONCLUSION

Non-attendance at both the BC and CRC-SPs tends to be associated with living in a lower SES score neighbourhood. In addition, non-attenders living in these lower SES neighbourhoods, were more often diagnosed with the unfavourable forms of cancer, as targeted by the specific CSPs. Since low screening uptake thus contributes to increasing inequalities in cancer survival, future outreach should be focused on engaging specific groups of people living in lower SES neighbourhoods carrying the highest risks.

### Author affiliations

<sup>1</sup>Health Campus The Hague, Leiden University Medical Center, The Hague, The Netherlands

<sup>2</sup>Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands

<sup>3</sup>Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands

<sup>4</sup>University Cancer Center Leiden | The Hague, Haaglanden Medical Center, The Hague, The Netherlands

**Acknowledgements** The authors wish to thank the national screening organisation, region South-West (Bevolkingsonderzoek Zuid-West) for providing data on screening examination, and the registration team of the Netherlands Comprehensive Cancer Organisation (IKNL) for the collection of data for the Netherlands Cancer Registry. (Since 1 January 2022, the five regional screening organisations merged into one organisation: Bevolkingsonderzoek Nederland).

**Contributors** THGB and FLB designed the study, collected and combined the datasets. Data analysis was undertaken by THGB, supervised by FLB, and in a later stage by LdM and ME. THGB drafted the first version of the paper. ORG and MEN helped to interpret the results. MEN acts as guarantor. All authors reviewed and edited the manuscript.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not applicable.

**Ethics approval** On forehand the Ethics Committee of the Leiden University Medical Centre issued a waiver of consent (G18.096).

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Used datasets are available from the corresponding author on reasonable request.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

### ORCID iDs

Thomas H G Bongaerts <http://orcid.org/0000-0002-3242-0486>

Frederike L Büchner <http://orcid.org/0000-0001-8977-5344>

Onno R Guicherit <http://orcid.org/0000-0003-4862-1394>

Mattijs E Numans <http://orcid.org/0000-0002-0368-5426>

## REFERENCES

- European Commission. Directorate-general for research and innovation, group of chief scientific advisors. Cancer screening in the European Union; 2022.
- von Karsa L, Patnick J, Segnan N, *et al*. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. *Endoscopy* 2013;45:51–9.
- Zielonke N, Gini A, Jansen EEL, *et al*. Evidence for reducing cancer-specific mortality due to screening for breast cancer in Europe: a systematic review. *Eur J Cancer* 2020;127:191–206.
- van Ballegooijen M, van den Akker-van Marle E, Patnick J, *et al*. Overview of important cervical cancer screening process values in European union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. *Eur J Cancer* 2000;36:2177–88.
- Rijksinstituut voor Volksgezondheid en Milieu. Population screening programmes. 2022. Available: <https://www.rivm.nl/node/99391>
- Rijksinstituut voor Volksgezondheid en Milieu. The national breast cancer screening programme. 2022. Available: <https://www.rivm.nl/en/breast-cancer-screening-programme> [Accessed May 2022].
- Rijksinstituut voor Volksgezondheid en Milieu. The national colorectal cancer screening programme. 2022. Available: <https://www.rivm.nl/en/colorectal-cancer-screening-programme>
- Young B, Robb KA. Understanding patient factors to increase uptake of cancer screening: a review. *Future Oncol* 2021;17:3757–75.
- Lynge E, Törnberg S, von Karsa L, *et al*. Determinants of successful implementation of population-based cancer screening programmes. *Eur J Cancer* 2012;48:743–8.
- World Health Organization. Cancer control: early detection. WHO guide for effective programmes. 2007.
- World Health Organization. National cancer control programmes: policies and managerial guidelines: world health organization; 2002.
- World Health Organization. Guide to cancer early diagnosis; 2017.
- Rijksinstituut voor Volksgezondheid en Milieu. Monitor bevolkingsonderzoek borstkanker. 2020. Available: <https://www.rivm.nl/bevolkingsonderzoek-borstkanker/professionals/monitoring-en-evaluatie>
- Rijksinstituut voor Volksgezondheid en Milieu. Monitor bevolkingsonderzoek darmkanker. 2020. Available: <https://www.rivm.nl/bevolkingsonderzoek-darmkanker/professionals/monitoring-en-evaluatie>
- Stichting Bevolkingsonderzoek Nederland Jaarbericht. 2020. Available: <https://www.jaarberichtbevolkingsonderzoeknederl.and2020.nl> [Accessed May 2022].
- Bongaerts THG, Büchner FL, Middelkoop BJ, *et al*. Determinants of (Non-)Attendance at the dutch cancer screening programmes: a systematic review. *J Med Screen* 2020;27:121–9.
- Bevolkingsonderzoek Zuid-West Jaarverslag. 2019. Available: [https://www.bevolkingsonderzoeknederland.nl/media/1442/jaarverslag-2019\\_def.pdf](https://www.bevolkingsonderzoeknederland.nl/media/1442/jaarverslag-2019_def.pdf) [Accessed Jan 2021].
- Netherlands Comprehensive Cancer Organisation. IKNL and the NCR. 2020. Available: <https://iknl.nl/en> [Accessed May 2022].
- Dutch Institute for Social Research. Sociaal economische statusscores per postcode. 2017. Available: <https://www.scp.nl/publicaties> [Accessed Mar 2019].
- Aarts MJ, Voogd AC, Duijm LEM, *et al*. Socioeconomic inequalities in attending the mass screening for breast cancer in the South of the Netherlands—associations with stage at diagnosis and survival. *Breast Cancer Res Treat* 2011;128:517–25.
- Deutekom M, van Rijn AF, Dekker E, *et al*. Uptake of faecal occult blood test colorectal cancer screening by different ethnic groups in the Netherlands. *Eur J Public Health* 2009;19:400–2.





- 22 Vermeer B, Van den Muijsenbergh M. The attendance of migrant women at the national breast cancer screening in the Netherlands 1997-2008. *Eur J Cancer Prev* 2010;19:195-8.
- 23 Naik H, Qiu X, Brown MC, *et al*. Socioeconomic status and lifestyle behaviours in cancer survivors: smoking and physical activity. *Curr Oncol* 2016;23:e546-55.
- 24 Kregting LM, Olthof EMG, Breekveldt ECH, *et al*. Concurrent participation in breast, cervical, and colorectal cancer screening in the Netherlands. *Eur J Cancer* 2022;175:180-6.
- 25 Lo SH, Waller J, Wardle J, *et al*. Comparing barriers to colorectal cancer screening with barriers to breast and cervical screening: a population-based survey of screening-age women in great Britain. *J Med Screen* 2013;20:73-9.
- 26 McCowan C, McSkimming P, Papworth R, *et al*. Comparing uptake across breast, cervical and bowel screening at an individual level: a retrospective cohort study. *Br J Cancer* 2019;121:710-4.
- 27 Rebolj M, Parmar D, Maroni R, *et al*. Concurrent participation in screening for cervical, breast, and bowel cancer in England. *J Med Screen* 2020;27:9-17.
- 28 GemeenteDen Haag. Den haag in cijfers. Available: <https://denhaag.incijfers.nl/dashboard/wijkprofielen> [Accessed Mar 2022].
- 29 Gemeente Den Haag. Den haag in cijfers/bevolking. 2021. Available: <https://denhaag.incijfers.nl/dashboard/Overzichten/Bevolking> [Accessed Mar 2022].
- 30 Gemeente Amsterdam. Stand van de bevolking Amsterdam. 2021. Available: [https://data.amsterdam.nl/datasets/bx\\_HyaOipADV-Q/stand-van-de-bevolking-amsterdam/?term=Stand+van+de+bevolking+Amsterdam](https://data.amsterdam.nl/datasets/bx_HyaOipADV-Q/stand-van-de-bevolking-amsterdam/?term=Stand+van+de+bevolking+Amsterdam) [Accessed Apr 2022].
- 31 Onderzoek010/Bevolking 2021. Available: <https://onderzoek010.nl/dashboard/onderzoek010/Bevolking> [Accessed Apr 2022].
- 32 Tudor Hart J. The inverse care law. *Lancet* 1971;297:405-12.
- 33 Woudstra AJ, Dekker E, Essink-Bot M-L, *et al*. Knowledge, attitudes and beliefs regarding colorectal cancer screening among ethnic minority groups in the Netherlands—a qualitative study. *Health Expect* 2016;19:1312-23.
- 34 de Nooijer DP, de Waart FG, van Leeuwen A, *et al*. Participation in the dutch national screening programme for uterine cervic cancer higher after invitation by a general practitioner, especially in groups with a traditional low level of attendance. *Ned Tijdschr Geneesk* 2005;149:2339-43.
- 35 Hermens RP, Tacke MA, Hulscher ME, *et al*. Attendance to Cervical cancer screening in family practices in the Netherlands. *Prev Med* 2000;30:35-42.
- 36 Brabers AEMDWN, Meijman HJ, De Jong JD. Wat beschouwen burgers als kernwaarden en kerntaken van de huisarts; 2019.